Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Retinoblastoma 1

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × Ranibizumab × Clear all
NCT01251978 2016-10-19

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

New England Retina Associates

Phase 2 Completed
10 enrolled 7 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡